Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
7 evidence topics · 6 sources
Clinical half-life as reported in January 2024
Estimated half-life by single-agent dose level as reported in April 2024
Clinical half-life as reported in February 2026
Exposure by dose level
Food effect with darolutamide
Preclinical solubility, oral bioavailability, and half-life
| Property | Rinzimetostat |
|---|---|
| Solubility | “11.7 mg/ml” |
| Mouse oral bioavailability | “64%” |
| Mouse half-life, oral | “3-5 hr PO” |
| Mouse half-life, intravenous | “2.5 hr IV” |
| Clinical half-life | “~20 hrs” |